The Latest Breaking News from Amgen

Where Amgen Stands With Analysts

Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:

Benzinga · Apr 28, 2022

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Apr 28, 2022

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015. 

Benzinga · Apr 28, 2022

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Exclusive: British government accused of indirectly helping to fund Putin’s war with £294m contracts

The Independent UK · Apr 17, 2022

Where Amgen Stands With Analysts

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Benzinga · Apr 12, 2022

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

Benzinga · Apr 11, 2022

$1000 Invested In Amgen 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 13.98%. Currently, Amgen has a market capitalization of $136.43 billion.

Benzinga · Apr 4, 2022

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.42% on an annualized basis.

Benzinga · Mar 15, 2022

A Bullish Sign Appears On Amgen's Chart

If history is any guide, there may be good fortune ahead for shares of Amgen (NASDAQ:AMGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga · Feb 23, 2022

Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer

Amgen Inc (NASDAQ: AMGN) announced the presentation of 

Benzinga · Feb 15, 2022